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ABSTRACT: Human dermal absorption of eight mono- to deca-brominated
diphenyl ethers (PBDEs) was investigated for the ﬁrst time using EPISKIN
human skin equivalent tissue. Using a standard in vitro protocol, EPISKIN
tissues mounted in specially designed diﬀusion cells were exposed to the
target PBDEs for 24 h. Estimated steady-state ﬂux (Jss) and permeation
coeﬃcients (Papp) across the skin increased with decreasing bromine
substitution from BDE-153 (Papp = 4.0 × 10
−4 cm/h) to BDE-1 (Papp =
1.1 × 10−2 cm/h). This was accompanied by an increase in the time required
to traverse the skin tissue into the receptor ﬂuid (lag time) from 0.25 h for
BDE-1 to 1.26 h for BDE-153. Papp values for the studied PBDEs were
correlated signiﬁcantly (P < 0.05) with physicochemical parameters like water
solubility and log KOW. While less brominated congeners achieved faster
dermal penetration, higher PBDEs displayed greater accumulation within the
skin tissue. The PBDEs thus accumulated represent a contaminant depot
from which they may be slowly released to the systemic circulation over a prolonged period. Maximal percutaneous penetration
was observed for BDE-1 (∼30% of the applied 500 ng/cm2 dose). Interestingly, BDE-183 and BDE-209 showed very low dermal
absorption, exempliﬁed by a failure to reach the steady state within the 24 h exposure period that was studied.
■ INTRODUCTION
Polybrominated diphenyl ethers (PBDEs) have found extensive
use worldwide as ﬂame retardants used in a wide variety of
commercial, domestic, and industrial applications. Applications
of PBDEs include electrical and electronic equipment [e.g.,
TVs, PCs, small domestic appliances (SDAs), etc.] in addition
to soft furnishings (e.g., sofas, mattresses, curtains, pillows,
etc.).1 Three technical PBDE formulations were commercially
available: Penta (consisting primarily of BDE-47 and BDE-99,
38−49% each, alongside smaller amounts of other tri- to hepta-
BDEs), Octa (a mixture of hexa- to deca-BDEs, the exact
congener composition varying substantially between the two
principal formulations marketed), and Deca (92−97% deca-
bromodiphenyl ether, BDE-209, with nona- and octa-BDEs).2
Deca-BDE has dominated worldwide production with a global
market demand of 56100 tons in 2001, compared to 7500 and
3790 tons for Penta-BDE and Octa-BDE formulations,
respectively.1
Because PBDEs are blended physically within rather than
bound chemically to polymeric materials, they migrate from
products, after which their persistence and bioaccumulative
properties lead to contamination of the environment, including
humans.3 This is of concern because of their potential
environmental and toxicological risks, including endocrine
disruption, neurodevelopmental and behavioral disorders,
hepatic abnormalities, and possibly cancer.4−6 Moreover, the
few data available from human epidemiological studies imply
eﬀects on male reproductive hormones,7,8 semen quality,9
thyroid hormone homeostasis,10 cryptorchidism,11 hormone
levels and fecundability in adult women,12 and lower birth
weight and length.13,14 Such evidence has contributed to
complete EU bans for the Penta- and Octa-BDE formulations
and restrictions on the use of Deca-BDE.15 In addition, PBDEs
associated with Penta- and Octa-BDE are listed under the
UNEP Stockholm Convention on persistent organic pollutants
(POPs), while Deca-BDE is currently under consideration for
listing under Annexes A, B, and/or C of the convention.16
Despite such restrictions, human exposure to PBDEs is likely to
continue for the foreseeable future, given their persistence and
the ubiquity of ﬂame-retarded consumer materials.17
The current understanding is that nonoccupational human
exposure to POPs occurs mainly via a combination of diet,
ingestion of indoor dust, dermal contact with dust/consumer
products, and inhalation of indoor air.18 While ingestion of
indoor dust is considered the major exposure pathway for many
individuals, especially for young children and toddlers,19 dermal
exposure (via contact with indoor dust and ﬂame-retarded
products) was predicted to be the second most important
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contributor to PBDE body burdens of adult Americans.20 In
Europe, while food was reported as the dominant pathway of
human exposure to PBDEs, dermal exposure to dust was
ranked in the upper quantiles of exposure routes contributing
to human body burdens with either food or dust ingestion.18
The signiﬁcance of the dermal route as a pathway of human
exposure to PBDEs was further highlighted by Watkins et al.,
who reported a signiﬁcant correlation between PBDE levels on
hand wipes (assumed to result from contact with contaminated
dust or ﬂame-retarded products) and PBDE concentrations in
serum from American adults. Moreover, concentrations of
PBDEs in indoor dust were strongly correlated with those in
hand wipes, and infrequent hand-washers had 3.3 times greater
levels of PBDEs in their handwipes than did frequent hand-
washers.21
Despite the potentially important contribution of dermal
uptake as a pathway of human exposure to PBDEs, very little is
known about the fraction of PBDEs that becomes bioavailable
to humans (i.e., reaches the systemic circulation) following
dermal contact. Such a lack of experimental data on the
absorbed fractions of various PBDEs following human dermal
exposure represents a research gap, which hinders accurate risk
assessment of these hazardous chemicals. Furthermore, while it
is known that less brominated PBDEs display toxicological
eﬀects stronger than those of more brominated congeners,22 no
experimental data about how the degree of bromination aﬀects
the human dermal bioavailability of PBDEs exist. Eﬀorts to
address this research gap are impeded by several diﬃculties,
including ethical and technical issues inherent to studies
involving human tissues, increasing restrictions on the use of
laboratory animals in toxicological studies, and the substantial
uncertainties associated with extrapolating data from animal
studies to humans because of interspecies variation (e.g., skin
barrier function, hair follicles, intercellular subcutaneous lipids,
etc.).23
To overcome these diﬃculties, this study applies in vitro
three-dimensional human skin equivalents (3D-HSE) as an
alternative method to animal and human testing for the
assessment of dermal uptake of selected PBDEs. 3D-HSE are
commercially available, fully diﬀerentiated, multilayer dermal
tissues that closely mimic the original human skin both
histologically and physiologically.24 Consequently, validated
protocols using 3D-HSE models have been approved by the
OECD (Organisation for Economic Co-operation and
Development) and ECVAM (European Centre for Validation
of Alternative Methods) for testing skin irritation, photo-
toxicity, and corrosion by xenobiotic chemicals.25,26 While
recent advances in 3D-HSE culture techniques have resulted in
improving their barrier function (up to 85%), it should be
noted that no artiﬁcial skin model has managed to reach 100%
of the barrier function of normal human skin so far. The
advantages and limitations of using in vitro 3D-HSE to study
the percutaneous penetration of various chemicals, including
organic FRs, have been comprehensively discussed else-
where.23,27 3D-HSE have been applied within the cosmetics
and pharmaceutical sectors to study dermal uptake of various
chemicals.22 Moreover, we recently validated their application
to study human dermal absorption of hexabromocyclodode-
canes (HBCDDs) and tetrabromobisphenol-A (TBBP-A)
against human ex vivo skin.28 The speciﬁc objectives of this
paper are (a) to assess percutaneous penetration of target
PBDEs in humans using an EPISKIN 3D-HSE model,29 (b) to
evaluate the inﬂuence of bromine substitution on the dermal
bioavailability of PBDEs, and (c) to provide the ﬁrst insights
into the dermal bioavailability of several PBDEs.
■ MATERIALS AND METHODS
All experiments were performed in a fashion that complied with
the principles of good laboratory practice and the OECD
guidelines for in vitro dermal absorption testing.29 The handling
instructions and performance characteristics of the EPISKIN
human skin equivalent model were also taken into consid-
eration. The study protocol received the required ethical
approval (ERN_12-1502) from the University of Birmingham’s
Medical, Engineering and Mathematics Ethical Review
Committee.
Human Skin Equivalents. EPISKIN RHE/L/13 human
skin equivalent kits were purchased from SkinEthic Labo-
ratories (Lyon, France). The RHE/L/13 tissue constructs are
1.07 cm2 human skin equivalents resembling the normal human
epidermis (Figure SI-1) histologically and physiologically
(www.episkin.com). The kit includes maintenance medium
(MM), which is a proprietary medium (DMEM, Dulbecco’s
modiﬁed Eagle’s medium), that allows acceptable diﬀerentiated
morphology of the tissue for ∼5 days upon receipt by end
users. Upon receipt, the EPISKIN tissues were equilibrated
Figure 1. Chemical structure and nomenclature of PBDEs used in this study.
Environmental Science & Technology Article
DOI: 10.1021/acs.est.5b03904
Environ. Sci. Technol. 2015, 49, 10976−10983
10977
D
ow
nl
oa
de
d 
by
 U
N
IV
 O
F 
BI
RM
IN
G
H
A
M
 o
n 
Se
pt
em
be
r 1
5,
 2
01
5 
| ht
tp:
//p
ubs
.ac
s.o
rg 
 
Pu
bl
ic
at
io
n 
D
at
e 
(W
eb
): 
Au
gu
st 
27
, 2
01
5 | 
doi
: 1
0.1
021
/ac
s.e
st.5
b03
904
overnight with the suppliers’ MM at 5% CO2 and 37 °C before
use in permeation experiments.
Chemicals and Standards. Standard solutions (50 μg/mL,
>99% pure) of target PBDE-1 (mono-BDE), PBDE-8 (di-
BDE), PBDE-28 (tri-BDE), PBDE-47 (tetra-BDE), PBDE-99
(penta-BDE), PBDE-153 (hexa-BDE), PBDE-183 (hepta-
BDE), and PBDE-209 (deca-BDE) (Figure 1) were purchased
from Wellington Laboratories (Guelph, ON). PBDE congeners
77 and 128 and [13C]BDE-209 used as internal (surrogate)
standards and PCB-129 used as a recovery determination
(syringe) standard were purchased from the same company. All
solvents and reagents used for extraction, cleanup, and
instrumental analysis of samples were of the highest available
purity and were obtained from Fisher Scientiﬁc (Lough-
borough, U.K.).
Dosing Solutions. Two diﬀerent concentration levels of (I)
5 ng/μL and (II) 10 ng/μL of each of the target PBDEs were
prepared in acetone. On the basis of the exposed surface area,
net doses of 500 and 1000 ng/cm2 were applied (inﬁnite dose
scenario) to each of the investigated skin tissues using an
appropriate volume (100 μL/cm2) of dosing solutions I and II,
respectively. Acetone was selected as the dosing vehicle on the
basis of its ability to dissolve the test compounds at the desired
levels and its minimal eﬀect on skin barrier functions. A
previous study of the eﬀect of organic solvents on the trans-
epidermal water loss (TEWL) as an indicator of skin barrier
revealed both acetone and hexane not to exhibit behavior
signiﬁcantly diﬀerent in this context from that of water, while a
mixture of chloroform and methanol [2:1 (v/v)] caused the
most signiﬁcant increase in TEWL.30
Permeation Assay Protocol. The permeation experiments
were performed using a static conﬁguration (Figure 2). On the
basis of the recommendation of the 3D-HSE providers, the
EPISKIN tissues were mounted in speciﬁc Franz-type
permeation devices constructed speciﬁcally for this model
(SkinEthic Laboratories, Lyon, France) with the stratum
corneum facing up. All experiments were performed in triplicate.
Following a 30 min equilibration, the tested chemicals were
applied onto the skin surface in the donor compartment. A
DMEM-based culture medium comprising several inorganic
salts, vitamins, amino acids, and nutrients (Table SI-1) was
used as the receptor ﬂuid, maintained at 32 ± 1 °C, and
magnetically stirred; 5% bovine serum albumin (BSA) was
added to the receptor ﬂuid to enhance the solubility of target
analytes, while the levels of test compounds in the donor
solutions were chosen to ensure that the concentrations in the
receptor ﬂuid during the experiment did not exceed 10% of the
saturation solubility (more details in the Supporting
Information).
At ﬁxed time points, aliquots of the receptor ﬂuid (2 mL)
were collected from the receptor compartment and immedi-
ately replaced with fresh ﬂuid. After 24 h, the entire receptor
ﬂuid was collected and the skin surface washed thoroughly with
cotton buds impregnated in the 1:1 (v/v) hexane/ethyl acetate
solution (ﬁve times). The tissues were removed from the
permeation devices, and both the donor and receptor
compartments were washed separately (5 × 2 mL) with the
Figure 2. General outline of the experimental protocol applied to study the percutaneous permeation of PBDEs.
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1:1 (v/v) hexane/ethyl acetate mixture. All samples were stored
at −20 °C until chemical analysis.
Sample Extraction and Chemical Analysis. Each
permeation assay generated ﬁve diﬀerent types of samples
comprising receptor ﬂuid at various time points, skin tissue,
cotton buds (used to thoroughly wipe the skin surface), the
donor compartment wash, and the receptor compartment wash.
The receptor ﬂuid, skin tissue, and cotton bud samples were
extracted according to a previously reported QuEChER-based
method31 (more details are provided as Supporting Informa-
tion).
The donor and receptor compartment washes were spiked
with 30 ng of the internal standard mixture (BDE-77, BDE-128,
and [13C]BDE-209) prior to direct evaporation under a gentle
stream of N2. Target analytes were reconstituted in 100 μL of
isooctane containing 100 pg/μL PCB-129 used as a recovery
determination (syringe) standard for quality assurance/quality
control (QA/QC) purposes.
Quantiﬁcation of target PBDEs was performed using a
TRACE 1310 GC instrument coupled to an ISQ single-
quadrupole mass spectrometer (Thermo Fisher Scientiﬁc,
Austin, TX) operated in negative chemical ionization (NCI)
mode using methane as the reagent gas according to a
previously described method.32 Separation of target PBDEs was
performed on an Agilent DB-5 capillary column (15 m × 0.25
mm, 0.1 μm) using helium as the carrier gas. The mass
spectrometer was run in selected ion monitoring (SIM) mode
with ion source, quadrupole, and mass transfer line temper-
atures set at 230, 150, and 300 °C, respectively. Further details
of the GC−NCI/MS method are provided as Supporting
Information.
Data Analysis and Statistical Methods. A quantitative
description of test compound permeation through the skin
barrier can be derived from Fick’s ﬁrst law of diﬀusion as
follows:33
= Δ
Δ
= Δ
Δ
J
m
tA
DK C
xss (1)
where Jss is the steady-state ﬂux (nanograms per square
centimeter per hour), Δm is the permeated mass (nanograms),
Δt is the time interval (hours), D is the diﬀusion coeﬃcient
(square centimeters per hour), K is the partition coeﬃcient, A
is the area (square centimeters), Δc is the concentration
diﬀerence across the membrane (nanograms per cubic
centimeter), and Δx is the thickness of the membrane
(centimeters).
When using inﬁnite-dose conﬁgurations, i.e., in which the
donor concentration far exceeds the concentration in the
receptor compartment (CD ≫ CA), ΔC can be replaced by the
known donor concentration, CD, and the permeated mass per
time is assumed to be constant. Therefore, the apparent
permeation coeﬃcient (Papp, in centimeters per hour), which
represents an independent measure of the membrane resistance
against permeation of the examined substance, can be
calculated as
=P
J
Capp
ss
D (2)
For each permeation experiment, cumulative amounts of the
permeated compounds in the receptor ﬂuid per unit area of
exposed skin (nanograms per square centimeter) were plotted
versus time (hours). Steady-state conditions were indicated by
a linear regression line [R2 ≥ 0.9; P ≤ 0.01 (Table SI-6)], the
slope of which represents the ﬂux (Jss). Determination of the
start and upper boundary of the linear range (i.e., steady-state
conditions) was achieved according to the method previously
described by Niedorf et al.33 (a summary ﬂowchart is provided
in Figure SI-3).
Results are presented as the arithmetic mean of three
replicates ± the standard deviation (SD). Statistical analysis was
performed using SPSS 13.0. Diﬀerences in skin permeation
were evaluated by the paired Student’s t test between two data
sets. A Games−Howell test was used for analysis of variance
(ANOVA) among several data sets with equal variances not
assumed; p < 0.05 was regarded to indicate a statistically
signiﬁcant diﬀerence.
QA/QC. Several forms of QA/QC measurement were
performed to check the performance of our permeation assay
protocol. A “ﬁeld” blank, comprising a skin tissue exposed to
solvents only and treated as a sample, was performed with each
sample batch (n = 5). None of the studied compounds were
above the limit of detection (LOD) in these ﬁeld blank
samples. Good recoveries of internal standards (>80%) were
obtained for all samples, indicating the high eﬃciency of the
extraction method (Table SI-2). The accuracy and precision of
the analytical method were tested via replicate analysis of NIST
SRM 2585 with certiﬁed values for trideca-BDEs. Furthermore,
method performance under the applied experimental con-
ditions was tested via matrix spikes of the EPISKIN tissues at
three diﬀerent concentration levels of the target PBDEs. Good
results were obtained (Table SI-3), indicating the suitability of
the applied analytical protocol for quantiﬁcation of target
PBDEs in the studied samples.
On the basis of the guidelines of the EPISKIN model, the
viability of the tissue was tested by the MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay
Table 1. Cumulative Levels (expressed as the average percentage ± the standard deviation of the applied dose) of Target
PBDEs in the Receptor Fluid following Exposure of EPISKIN to 500 ng/cm2 of Target PBDEs
time (h) BDE-1 BDE-8 BDE-28 BDE-47 BDE-99 BDE-153 BDE-183 BDE-209
0.25 NDa ND ND ND ND ND ND ND
0.50 0.25 ± 0.09 0.10 ± 0.04 0.07 ± 0.03 0.04 ± 0.01 ND ND ND ND
1.00 1.06 ± 0.28 0.41 ± 0.05 0.20 ± 0.02 0.13 ± 0.02 0.08 ± 0.01 0.03 ± 0.01 ND ND
2.00 1.98 ± 0.61 0.82 ± 0.07 0.31 ± 0.09 0.21 ± 0.09 0.07 ± 0.04 0.04 ± 0.01 ND ND
6.00 5.07 ± 1.07 1.88 ± 0.65 0.46 ± 0.31 0.48 ± 0.32 0.43 ± 0.15 0.13 ± 0.05 ND ND
10.00 10.20 ± 1.89 4.34 ± 1.72 1.59 ± 1.56 0.97 ± 0.82 0.57 ± 0.77 0.33 ± 0.03 ND ND
12.00 14.24 ± 2.12 6.75 ± 2.24 2.19 ± 1.36 1.56 ± 0.89 0.86 ± 0.84 0.46 ± 0.02 0.03 ± 0.01 ND
18.00 20.43 ± 2.54 8.68 ± 2.17 2.77 ± 1.43 2.23 ± 0.88 1.29 ± 1.07 0.68 ± 0.04 0.04 ± 0.01 ND
24.00 24.92 ± 2.71 11.08 ± 2.43 4.23 ± 1.68 2.85 ± 1.09 1.96 ± 1.26 0.89 ± 0.11 0.05 ± 0.01 ND
aNot detected (<0.02% of the applied dose for all congeners or 0.05% for BDE-209).
Environmental Science & Technology Article
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using a standard kit purchased from the tissue provider.
Acceptable MTT results (i.e., Formazan concentration of ≥1.5
mg/mL) were achieved until 24 h of exposure under the
speciﬁed test conditions, prior to dropping below the
recommended level of Formazan at longer times. Therefore,
exposure of EPISKIN tissues to the test PBDE mixtures was
terminated after 24 h.
Both positive and negative control experiments were
conducted alongside each sample batch. Positive controls
involved the exposure of the test tissue to Triton X-100 that
showed ∼100% permeation (n = 5; 97 ± 4%), while negative
controls showed 0% penetration of decabromodiphenyl ethane
after exposure for 24 h. The integrity of the skin membrane was
tested using visual microscopic inspection and the standard
methylene blue (BLUE) method.34 All EPISKIN tissues used in
this study passed all the QA/QC tests mentioned above.
■ RESULTS AND DISCUSSION
Percutaneous Penetration. The studied PBDE congeners
displayed wide variability in their ability to penetrate the skin
under the applied experimental conditions (Table 1). Results
revealed that the degree of dermal penetration was inversely
proportional to the degree of PBDE bromination. Maximal
penetration was observed for BDE-1 with ∼30% of the applied
dose detected in the receptor ﬂuid after exposure for 24 h,
while the more environmentally abundant BDE-47 and BDE-99
showed an average absorption of ∼3 and 2%, respectively
(Table 1). Interestingly, BDE-209 was not detected in the
receptor ﬂuid after 24 h, indicating low dermal bioavailability of
this congener in humans (Table 1). Under the inﬁnite-dose
conﬁguration applied in this study, the concentration gradient
is maximized and diﬀusion/penetration through the skin
becomes the rate-limiting step. Therefore, the absorbed
percentages are likely a function of the applied dose and can
vary with the concentration of xenobiotic applied to the skin.29
However, we have opted to present our results as percentages
of the speciﬁed dose (Table 1) to facilitate comparison of
percutaneous penetration among the various PBDE congeners
studied under the applied test protocol.
Results of the mass balance studies were expressed as falling
into three major compartments: (1) the directly absorbed dose
(cumulative concentration in the receptor ﬂuid over 24 h +
receptor compartment rinse), (2) the skin (concentration in
the skin tissue after 24 h), and (3) the unabsorbed dose
(concentration in the skin surface wipes after 24 h + donor
compartment rinse) (Table 2). Data for compartment category
(2) revealed all target PBDEs accumulate in the skin tissue to
varying degrees. While the proportion of the applied PBDE
dose that accumulated in the skin increased with increasing
bromine substitution from BDE-1 (∼18%) to BDE-153
(∼37%), this proportion dropped steeply from BDE-183
(∼13%) to BDE-209 (8%) (Figure 3). The increased level of
accumulation within the skin of mono- through hexa-BDEs is
similar to what was reported for polychlorinated biphenyls
(PCBs) in male rats. This in vivo rat skin model favored the
rapid absorption of lower PCBs (mono- and dichlorinated),
while higher PCBs (hexachlorinated) penetrated less rapidly
but showed a higher level of accumulation in the skin prior to
entering the systemic circulation. This was mainly attributed to
the physicochemical parameters of the studied PCBs, which
allowed the more polar mono-PCBs to penetrate faster through
the water-rich viable epidermis. More lipophilic hexa-PCBs
Table 2. Distribution of Target BFRs (expressed as the average percentage ± the standard deviation of exposure dose) in
Diﬀerent Fractions of the in Vitro Diﬀusion System following the 24 h Exposure to 500 ng/cm2 of the Studied PBDEs
BDE-1 BDE-8 BDE-28 BDE-47 BDE-99 BDE-153 BDE-183 BDE-209
absorbeda 24.92 ± 2.71 11.08 ± 2.43 4.23 ± 1.68 2.85 ± 1.09 1.96 ± 1.26 0.89 ± 0.11 0.05 ± 0.01 NDc
unabsorbedb 51.72 ± 3.93 58.11 ± 4.28 58.97 ± 5.16 56.66 ± 4.81 57.61 ± 4.78 56.02 ± 5.67 81.57 ± 5.41 85.35 ± 4.95
skin 17.69 ± 1.75 21.60 ± 1.83 27.29 ± 2.14 33.10 ± 1.87 33.98 ± 2.31 37.49 ± 2.18 12.78 ± 1.24 8.38 ± 1.31
sum 94.33 ± 7.52 90.79 ± 8.31 90.49 ± 8.91 92.61 ± 7.68 93.54 ± 8.27 94.39 ± 7.90 94.40 ± 6.62 93.73 ± 6.22
aComprises cumulative concentrations in the receptor ﬂuid over 24 h + receptor compartment rinse. bComprises concentrations in the skin surface
wipes after 24 h + donor compartment rinse. cNot detected (<0.02% of applied dose for all congeners or 0.05% for BDE-209).
Figure 3. Percent of applied dose (500 ng/cm2) of target PBDEs absorbed (present in the receptor compartment), unabsorbed (remaining in the
donor compartment and on skin surface), and accumulated in the skin tissue following the 24 h exposure.
Environmental Science & Technology Article
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were hypothesized to accumulate for longer in the lipid-rich
stratum corneum prior to diﬀusion through the viable epidermis
at a slower rate.35 In addition to the inﬂuence of compound-
speciﬁc physicochemical parameters, we hypothesize that
dermal metabolism may also aﬀect the rate of penetration
and accumulation of various PBDEs through the skin. Viable
epidermal cells possess cytochrome P450 with activities that are
∼80% of hepatic activities. Recent studies have shown various
PBDEs to be metabolized by cytochrome P450 to more polar
metabolites.36,37 Biotransformation of diﬀerent PBDEs by
viable human epidermal cells can cause disposition of the
metabolized congeners at variable rates. This is likely to
inﬂuence the concentration gradient of each congener across
the various layers of skin and have a substantial eﬀect on the
overall rate of percutaneous penetration of the studied
compound. However, further research is required to investigate
the inﬂuence of dermal metabolism on the percutaneous
penetration of PBDEs. The low dermal accumulation of BDE-
183 and BDE-209 may be attributed to their large molecular
mass and volume, which may hinder their partitioning to the
stratum corneum and subsequent absorption by keratinocytes.38
An extensive survey of the available literature reveals very few
studies of the dermal absorption of PBDEs in animals and/or
humans. In one, radiolabeled BDE-209 showed very low
percutaneous penetration (<1%) through female mice skin
exposed in vitro at three concentration levels. Approximately 2−
20% of the dose remained in the skin after exposure for 24 h.39
If we keep in mind the fact that mouse skin has shown a
permeability (7−9-fold) to several chemicals much higher than
that of human skin,39 these ﬁndings are generally in agreement
with our results for BDE-209, where no penetration to the
receptor ﬂuid was observed after exposure for 24 h, but ∼8% of
the dose was detected in the skin tissue (Table 2). While
human absorption of BDE-209 via the dermal route appears to
be minimal, this may not be the case for other exposure
pathways, including dust ingestion and/or diet. The bioavail-
ability of more brominated PBDEs, including BDE-209, to
humans is evident from the results of several biomonitoring
studies reporting hepta- to deca-BDEs in various tissues,
including human milk, blood, placenta, and adipose tissue.40,41
Female mice exposed to 1 mg of [14C]BDE-47/kg of body
weight in acetone applied to a hairless 2 cm2 skin patch showed
∼62% absorption of the administered dose after 5 days, while
15% remained at the site of application.42 Another in vitro study
using frozen, nonviable skin reported a 7.6-fold increase in the
percentage of [14C]BDE-47 absorbed through rat skin
compared with human skin. In the latter report, human skin
patches were exposed in vitro to a single dose of ∼10 mg of
[14C]BDE-47/cm2. Results revealed 3.13% of the initial dose
was absorbed after exposure for 24 h, while 33% of the applied
dose remained in the skin.43 Despite the use of a single large
dose and a 0.9% (w/v) NaCl solution in water as a receptor
ﬂuid, the results of Roper et al.43 are generally in good
agreement with our ﬁndings for BDE-47 (Table 2).
To the best of our knowledge, this is the ﬁrst report of
human percutaneous penetration of BDE-1, -8, -28, -99, -153,
and -183.
Dermal Flux (Jss) and Permeation Coeﬃcients (Papp).
Steady-state ﬂux (Jss) and skin permeation coeﬃcient (Papp)
values were derived for the studied PBDEs (Table 3 and
Figures SI-4 and SI-5). It was not possible to estimate either
property for BDE-183 and BDE-209 because of their low
percutaneous penetration and failure to reach steady state
within our 24 h exposure period.
Results show a decreased ﬂux across the skin and higher
resistance to percutaneous penetration with increasing bromine
substitution from mono- to hexa-PBDEs (Table 3). Variation in
the degree of Br substitution across mono- to deca-brominated
PBDE congeners is accompanied by substantial changes in their
key physicochemical parameters, including molecular weight,
water solubility, KOW, and vapor pressure (Table SI-4). The
inﬂuence of these parameters on the experimentally derived
Papp values for PBDEs targeted in this study (Table 3) was
investigated. Results revealed a signiﬁcantly positive correlation
(P < 0.05) between Papp values of the studied mono- through
hexa-BDEs and the water solubility and vapor pressure of these
congeners (Table SI-4). A signiﬁcant negative correlation (P <
0.05) was observed between Papp and log KOW, as well as the
molecular weight of the studied PBDEs. It was not possible to
include BDE-183 and BDE-209 in this statistical analysis
because of the lack of Papp values for these congeners as a result
of their slow penetration where no steady state was achieved
within 24 h. However, our results for mono- through hexa-
BDEs are in agreement with previous reports for percutaneous
penetration of PCBs35 and are generally in line with Lipinski’s
rule of ﬁve, indicating that an increase in a chemical’s molecular
weight or log Kow or a decrease in its water solubility is a factor
that likely induces higher dermal resistance to the penetration
of this compound.38
Following the application of a test compound to the skin, it
needs to partition into the stratum corneum and diﬀuse through
the epidermal cells before reaching the receptor ﬂuid. This
results in a lag time, tlag, with nondetectable ﬂux. The tlag is
represented by the time intercept (i.e., x-axis intercept) of the
regression line over the linear region of the permeation curve
(Figures SI-4 and SI-5). Hence, tlag can be calculated from eq 3:
=t b
Jlag
0
ss (3)
where b0 refers to the y-axis intercept of the linear regression
line and Jss is the slope.
Estimated lag times (Table 3) for the studied PBDEs varied
between 0.25 and 1.26 h for BDE-1 and BDE-153, respectively.
This is in accordance with the ability of less brominated
congeners to diﬀuse quickly through the dermal tissue to the
receptor ﬂuid, while the more lipophilic, more brominated
congeners are likely to accumulate within the stratum corneum.
The mass of the chemical retained within the skin tissue may
form a depot from which prolonged slow release may occur
into the receptor ﬂuid (bloodstream). However, dermal
absorption is a dynamic process. Therefore, a certain chemical
absorbed into the stratum corneum will continue to transfer into
viable tissue layers. If there is no loss of the chemical present in
Table 3. Steady-State Flux, Permeation Coeﬃcient, and Lag
Time Values Estimated from Exposure of EPISKIN to 500
ng of Target PBDEs/cm2 for 24 h
ﬂux (ng/cm2 h) permeation coeﬃcient (cm/h) lag time (h)
BDE-1 5.45 1.09 × 10−2 0.25
BDE-8 2.42 4.84 × 10−3 0.42
BDE-28 0.88 1.76 × 10−3 0.82
BDE-47 0.63 1.26 × 10−3 0.90
BDE-99 0.40 8.00 × 10−4 1.10
BDE-153 0.20 4.00 × 10−4 1.26
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the skin by metabolism, irreversible binding, evaporation, or
desquamation, then the mass of the chemical, which entered
the skin during the exposure period, will eventually become
available to the body.44
Implications for Human Exposure. Our results indicate
that following exposure of a unit area of human skin to a
mixture of PBDEs with varying degrees of bromination, less
brominated congeners achieve comparatively rapid penetration
of the systemic circulation (Table 3). In contrast, more
brominated congeners penetrate more slowly through the skin
layers to the blood. However, these higher PBDEs will achieve
higher levels of accumulation within the skin layers (Table 2).
This is likely due to the time required for the more lipophilic,
higher-molecular weight PBDEs to penetrate from the stratum
corneum through the aqueous-based viable epidermis prior to
reaching the bloodstream.44 Durrheim et al. established
experimentally that skin stripped of its stratum corneum is not
inﬁnitely permeable; rather, it retains a residual resistance due
to the diﬀusional barrier of the underlying viable tissue. Because
the diﬀusive medium for a given chemical compound in the
viable epidermis is essentially aqueous, this layer displays more
resistance to the diﬀusion of highly lipophilic compounds.45
We therefore argue that for the purposes of risk assessment,
the total mass of a chemical that becomes systemically available
over time following exposure should be considered. Indications
from our study are that this value is better expressed by the
mass of the target compound that has entered the skin, rather
than by that which has traversed the skin. This is because the
amount of chemical entering the skin exceeds that exiting the
skin (Figure SI-6).44 Furthermore, the mass of chemical
accumulated within the skin tissue is likely to form a
contaminant depot, which may release the compound slowly
to the bloodstream over a prolonged period of time.46
Moreover, for higher-molecular weight PBDEs such as BDE-
209, metabolism of this skin depot may result in exposure to
more toxic lower-molecular weight PBDEs that were not
present in the matrix to which the external skin barrier was
exposed.
Therefore, the results for percutaneous penetration of BDE-
183 and BDE-209 in this study should be regarded with caution
in the context of exposure assessment. Although the
percutaneous penetration for these congeners over 24 h was
almost negligible (Table 2), it should be noted that both
compounds accumulated within the skin to varying degrees and
may slowly reach the systemic circulation over a prolonged
period, even after the exposure is terminated.46 Hence, the
results of this in vitro study cannot be considered as conclusive
evidence that BDE-209 is not bioavailable to humans via the
dermal exposure pathway.
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